Engineered Treg Cell Composition for Stable FOXP3 in Type 1 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 1 diabetes (T1D) is a chronic autoimmune disease with no cure, requiring lifelong insulin administration and posing challenges in maintaining blood glucose control, leading to severe complications and quality of life issues, especially in pediatric patients.
Innovation Solution
Genetically modified regulatory T (EngTreg) cells are engineered with dual-edited nucleic acids in the TRAC and FOXP3 loci to express a chemically inducible signaling complex, allowing controlled proliferation and stable suppressive function in inflammatory environments, targeting islet cell antigens to mitigate autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous insulin therapy is administered to control hyperglycaemia in T1D patients, then blood glucose levels can be managed, but the patient requires lifelong daily monitoring and injection, significantly impacting quality of life and creating a chronic burden
Solution Approach 1:
The patent employs engineered Treg cells that autonomously suppress autoimmune responses against pancreatic beta cells, enabling the immune system to self-regulate and protect insulin-producing cells without requiring external insulin administration or monitoring by the patient
Solution Approach 2:
The engineered Treg cells are designed to act preventively by suppressing autoimmune responses before they can destroy remaining beta cells, particularly during the remission period when islet cells are still present but vulnerable to immune attack
2Reliability
If Treg cells are used to suppress autoimmune responses in T1D, then beta cell protection may be achieved, but the cells must maintain stable FOXP3 expression in inflammatory environments to prevent transdifferentiation into inflammatory T effector cells
Solution Approach 1:
The patent introduces an artificial promoter as an intermediary element that sits between the TSDR and FOXP3 coding sequence, acting as a constitutive driver that overrides TSDR methylation-mediated silencing and ensures stable FOXP3 expression even in inflammatory environments where endogenous promoters would be suppressed
Solution Approach 2:
The patent modifies the regulatory parameters of FOXP3 expression by inserting an artificial promoter with constitutive activity, changing the expression pattern from being subject to epigenetic silencing (TSDR methylation) to being continuously active, thereby stabilizing Treg identity against inflammatory-induced transdifferentiation
3Productivity
If engineered Treg cells are expanded in vitro to increase therapeutic dosage, then more cells are available for treatment, but the expansion process must be controlled to maintain cell quality and functionality
Solution Approach 1:
The patent employs periodic or controlled stimulation protocols during in vitro expansion, using intermittent antigen exposure or cytokine treatment to drive proliferation while maintaining Treg phenotype and suppressive function, preventing exhaustion or transdifferentiation that would occur with continuous stimulation
Data Source
AI summary
Described herein are compositions and methods for engineering Treg cells for treatment of diabetes. The engineered Treg cells provided herein may be dual-edited (i.e., edited in two different loci in the cell genome), a first locus being the FOXP3 locus and the second locus being the TRAC locus. The engineering of dual-edited Treg cells as provided here may include selective expansion of dual-edited cells using a ligand that initiates and/or maintains IL-2 signal transduction in dual-edited cells. The engineering of dual-edited Treg cells as provided here may stably express FoxP3 and an exogenous TCR.